ProQR Therapeutics (PRQR) Stock Rating Upgraded by Zacks Investment Research

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

PRQR has been the subject of several other research reports. ValuEngine cut shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of ProQR Therapeutics in a report on Tuesday, October 30th. Chardan Capital reiterated a “buy” rating and set a $9.00 price target on shares of ProQR Therapeutics in a report on Monday, August 13th. BidaskClub upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 24th. Finally, Evercore ISI began coverage on shares of ProQR Therapeutics in a report on Tuesday, September 18th. They set an “outperform” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.00.

NASDAQ PRQR traded down $1.86 on Wednesday, hitting $18.66. 5,734 shares of the stock were exchanged, compared to its average volume of 283,385. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.26. ProQR Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $24.00. The stock has a market capitalization of $817.59 million, a PE ratio of -10.37 and a beta of 0.54.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.10. On average, equities research analysts expect that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 28,025 shares in the last quarter. Millennium Management LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $1,426,000. Ardsley Advisory Partners acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $365,000. Jennison Associates LLC boosted its holdings in shares of ProQR Therapeutics by 1.0% in the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock valued at $21,763,000 after buying an additional 30,831 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC boosted its holdings in shares of ProQR Therapeutics by 50.0% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $657,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 28.55% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Further Reading: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply